Loading patent…
AssigneeTheravance Biopharma R&D IP, LLC
InventorsAdam D. Hughes, Erik Fenster, Melissa Fleury, Anne-Marie Beausoleil, Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
Estimating the term…
In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
A compound of the structure:
(2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid.
A crystalline form of calcium (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-4-(2-ethoxy-2-oxoacetamido)-2-(hydroxymethyl)-2-methylpentanoate.
Dependencies are inferred from the claim text.